193 related articles for article (PubMed ID: 35637731)
1. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type
Chao J; Feng L; Ye P; Chen X; Cui Q; Sun G; Zhou T; Tian E; Li W; Hu W; Riggs AD; Matalon R; Shi Y
iScience; 2022 Jun; 25(6):104391. PubMed ID: 35637731
[TBL] [Abstract][Full Text] [Related]
2. Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.
Feng L; Chao J; Tian E; Li L; Ye P; Zhang M; Chen X; Cui Q; Sun G; Zhou T; Felix G; Qin Y; Li W; Meza ED; Klein J; Ghoda L; Hu W; Luo Y; Dang W; Hsu D; Gold J; Goldman SA; Matalon R; Shi Y
Adv Sci (Weinh); 2020 Dec; 7(23):2002155. PubMed ID: 33304759
[TBL] [Abstract][Full Text] [Related]
3. Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders.
Feng L; Chao J; Ye P; Luong Q; Sun G; Liu W; Cui Q; Flores S; Jackson N; Shayento ANH; Sun G; Liu Z; Hu W; Shi Y
Adv Sci (Weinh); 2023 Aug; 10(23):e2206910. PubMed ID: 37271923
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
5. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
7. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
8. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
9. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
10. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
11. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
Exp Anim; 2024 Mar; ():. PubMed ID: 38538326
[TBL] [Abstract][Full Text] [Related]
12. Canavan disease: studies on the knockout mouse.
Matalon R; Michals-Matalon K; Surendran S; Tyring SK
Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
[TBL] [Abstract][Full Text] [Related]
13. The pathogenesis of, and pharmacological treatment for, Canavan disease.
Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
[TBL] [Abstract][Full Text] [Related]
14. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
Kaul R; Balamurugan K; Gao GP; Matalon R
Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
[TBL] [Abstract][Full Text] [Related]
15. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease.
Surendran S; Rady PL; Michals-Matalon K; Quast MJ; Rassin DK; Campbell GA; Ezell EL; Wei J; Tyring SK; Szucs S; Matalon R
Brain Res Bull; 2003 Aug; 61(4):427-35. PubMed ID: 12909286
[TBL] [Abstract][Full Text] [Related]
16. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
[TBL] [Abstract][Full Text] [Related]
17. Feline Spongy Encephalopathy With a Mutation in the
Takaichi Y; Chambers JK; Shiroma-Kohyama M; Haritani M; Une Y; Yamato O; Nakayama H; Uchida K
Vet Pathol; 2021 Jul; 58(4):705-712. PubMed ID: 33779415
[TBL] [Abstract][Full Text] [Related]
18. Loss of central auditory processing in a mouse model of Canavan disease.
von Jonquieres G; Froud KE; Klugmann CB; Wong AC; Housley GD; Klugmann M
PLoS One; 2014; 9(5):e97374. PubMed ID: 24826990
[TBL] [Abstract][Full Text] [Related]
19. Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease.
Surendran S; Shihabuddin LS; Clarke J; Taksir TV; Stewart GR; Parsons G; Yang W; Tyring SK; Michals-Matalon K; Matalon R
Brain Res Dev Brain Res; 2004 Oct; 153(1):19-27. PubMed ID: 15464214
[TBL] [Abstract][Full Text] [Related]
20. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
